0000885590-20-000023.txt : 20200429 0000885590-20-000023.hdr.sgml : 20200429 20200429170240 ACCESSION NUMBER: 0000885590-20-000023 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200429 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20200429 DATE AS OF CHANGE: 20200429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bausch Health Companies Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14956 FILM NUMBER: 20831352 BUSINESS ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 BUSINESS PHONE: 514-744-6792 MAIL ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 FORMER COMPANY: FORMER CONFORMED NAME: Valeant Pharmaceuticals International, Inc. DATE OF NAME CHANGE: 20100928 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 8-K 1 a8k42920agmresults.htm 8-K Document
false0000885590 0000885590 2020-04-29 2020-04-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

April 29, 2020 
Date of report (Date of earliest event reported)
 
Bausch Health Companies Inc.
(Exact name of registrant as specified in its charter)
British Columbia
,
Canada
001-14956
98-0448205
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
2150 St. Elzéar Blvd. West, Laval, Québec, Canada H7L 4A8
(Address of Principal Executive Offices) (Zip Code)

(514) 744-6792
(Registrant's telephone number, including area code)
 
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Shares, No Par Value
BHC
New York Stock Exchange
Toronto Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐    





Item 5.07
Submission of Matters to a Vote of Security Holders.
On April 28, 2020, Bausch Health Companies Inc. (the “Company”) held its Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the shareholders of the Company voted on the following four proposals, each of which is described in detail in the Company’s Management Proxy Circular and Proxy Statement. The results of each matter voted upon are as follows:
Proposal No. 1: Election of Directors. The shareholders elected the following individuals to the Company’s Board of Directors, to serve until the close of the Company’s 2021 Annual Meeting of Shareholders, their successors are duly elected or appointed, or such director’s earlier resignation or removal:
Name
 
For
 
Withheld
 
Broker Non-Votes
 
 
 
 
 
 
 
Richard U. De Schutter
 
216,315,704
 
5,259,134
 
59,178,282
D. Robert Hale
 
211,714,041
 
9,860,797
 
59,178,282
Dr. Argeris (Jerry) N. Karabelas
 
215,596,446
 
5,978,392
 
59,178,282
Sarah B. Kavanagh
 
217,011,297
 
4,563,541
 
59,178,282
Joseph C. Papa
 
212,494,697
 
9,080,141
 
59,178,282
John A. Paulson
 
219,853,068
 
1,721,770
 
59,178,282
Robert N. Power
 
208,740,697
 
12,834,141
 
59,178,282
Russel C. Robertson
 
215,372,886
 
6,201,952
 
59,178,282
Thomas W. Ross, Sr.
 
215,468,972
 
6,105,866
 
59,178,282
Andrew C. von Eschenbach, M.D.
 
219,493,913
 
2,080,925
 
59,178,282
Amy B. Wechsler, M.D.
 
216,271,318
 
5,303,520
 
59,178,282
Proposal No. 2: Advisory Vote on Executive Compensation. The shareholders approved, on a non-binding advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in the Compensation Discussion and Analysis section, executive compensation tables and accompanying narrative discussions contained in the Management Proxy Circular and Proxy Statement.
For
 
Against
 
Abstain
 
Broker Non-Votes
 
 
 
 
 
 
 
197,628,762
 
22,998,724
 
947,352
 
59,178,282
The Company has decided to include an advisory vote on executive compensation in its proxy materials every year until the next required vote on the frequency of advisory votes on executive compensation.
Proposal No. 3: Approval of an amendment to the Company’s Amended and Restated 2014 Omnibus Incentive Plan. The shareholders approved the amendment to the Company’s Amended and Restated 2014 Omnibus Incentive Plan (the “2014 Plan”) to increase the number of common shares, no par value, of the Company available for issuance under the 2014 Plan.
For
 
Against
 
Abstain
 
Broker Non-Votes
 
 
 
 
 
 
 
198,079,153
 
22,638,569
 
857,116
 
59,178,282




Proposal No. 4: Appointment of the Independent Registered Public Accounting Firm. The shareholders appointed PricewaterhouseCoopers LLP as the auditors for the Company to hold office until the close of the 2021 Annual Meeting of Shareholders and authorized the Company’s Board of Directors to fix the auditors’ remuneration.
For
 
Withheld
 
 
 
275,019,010
 
5,734,110





SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 29, 2020
 
 
BAUSCH HEALTH COMPANIES INC.
 
 
 
 
 By:
/s/ Christina M. Ackermann
 
Christina M. Ackermann
 
Executive Vice President and General Counsel


 EX-101.SCH 2 bhc-20200429.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Document link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 3 bhc-20200429_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 4 bhc-20200429_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 bhc-20200429_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover page. Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Country Entity Address, Country Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 6 bhc-20200429_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT JSON 7 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a8k42920agmresults.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "bhc-20200429_cal.xml" ] }, "definitionLink": { "local": [ "bhc-20200429_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "a8k42920agmresults.htm" ] }, "labelLink": { "local": [ "bhc-20200429_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "bhc-20200429_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "bhc-20200429.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bhc", "nsuri": "http://www.bauschhealth.com/20200429", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a8k42920agmresults.htm", "contextRef": "D2020Q2Apr29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document", "role": "http://www.bauschhealth.com/role/Document", "shortName": "Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a8k42920agmresults.htm", "contextRef": "D2020Q2Apr29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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a8k42920agmresults_htm.xml IDEA: XBRL DOCUMENT 0000885590 2020-04-29 2020-04-29 false 0000885590 8-K 2020-04-29 Bausch Health Companies Inc. A1 CA 001-14956 98-0448205 2150 St. Elzéar Blvd. West Laval QC CA H7L 4A8 514 744-6792 false false false false Common Shares, No Par Value BHC NYSE false XML 12 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document
Apr. 29, 2020
Cover page.  
Document Type 8-K
Document Period End Date Apr. 29, 2020
Entity Registrant Name Bausch Health Companies Inc.
Entity Incorporation, State or Country Code A1
Entity Address, Country CA
Entity File Number 001-14956
Entity Tax Identification Number 98-0448205
Entity Address, Address Line One 2150 St. Elzéar Blvd. West
Entity Address, City or Town Laval
Entity Address, State or Province QC
Entity Address, Postal Zip Code H7L 4A8
City Area Code 514
Local Phone Number 744-6792
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, No Par Value
Trading Symbol BHC
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Central Index Key 0000885590
Amendment Flag false

ZIP 13 0000885590-20-000023-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000885590-20-000023-xbrl.zip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end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 0001000 - Document - Document Sheet http://www.bauschhealth.com/role/Document Document Cover 1 false false All Reports Book All Reports a8k42920agmresults.htm bhc-20200429.xsd bhc-20200429_cal.xml bhc-20200429_def.xml bhc-20200429_lab.xml bhc-20200429_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true